198 related articles for article (PubMed ID: 35525183)
1. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.
Kiesewetter B; Mazal P; Kretschmer-Chott E; Mayerhoefer ME; Raderer M
ESMO Open; 2022 Jun; 7(3):100478. PubMed ID: 35525183
[TBL] [Abstract][Full Text] [Related]
2. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
4. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
5. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
[TBL] [Abstract][Full Text] [Related]
6. Value of [
Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
[TBL] [Abstract][Full Text] [Related]
7. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India.
Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H
J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479
[TBL] [Abstract][Full Text] [Related]
8. Role of Somatostatin Signalling in Neuroendocrine Tumours.
Rogoza O; Megnis K; Kudrjavceva M; Gerina-Berzina A; Rovite V
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163374
[TBL] [Abstract][Full Text] [Related]
9. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
[TBL] [Abstract][Full Text] [Related]
12. Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging.
Refardt J; Zandee WT; Brabander T; Feelders RA; Franssen GJH; Hofland LJ; Christ E; de Herder WW; Hofland J
Endocr Relat Cancer; 2020 Nov; 27(11):615-624. PubMed ID: 33032265
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
14. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
15. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
17. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E; Argalia G; Zanoni L; Fanti S; Ambrosini V
Curr Treat Options Oncol; 2022 May; 23(5):703-720. PubMed ID: 35325412
[TBL] [Abstract][Full Text] [Related]
18. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
19. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
20. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].
Haug AR; Assmann G; Rist C; Tiling R; Schmidt GP; Bartenstein P; Hacker M
Radiologe; 2010 Apr; 50(4):349-54. PubMed ID: 20333502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]